Bambusa Therapeutics (BBTX) vs Immatics N.V. (IMTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immatics N.V. is the larger company by market cap ($878.6 million vs $815.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBTX | IMTX |
|---|---|---|
| Share price | $16.00 | $5.77 |
| Market cap | $815.08M | $878.58M |
| 1-day change | +2.89% | -3.03% |
| YTD return | — | -45.05% |
| 1-year return | — | -43.43% |
| 5-year return | — | -48.57% |
| EPS (TTM) | $-1.73 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.65 | $12.41 |
| 52-week low | $13.60 | $5.72 |
| Distance from 52-week high | -9.35% | -53.51% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +176.78% |
| Average volume | 359.41K | 962.74K |
| Shares outstanding | 50.94M | 152.27M |
| Employees | 26 | 721 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bambusa Therapeutics
BBTX stock →Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees
BBTX vs IMTX FAQ
Which is bigger, Bambusa Therapeutics or Immatics N.V.?
Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $815.08M for Bambusa Therapeutics (BBTX).
Are Bambusa Therapeutics and Immatics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.